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S U M M A R Y
Objective: Clinically, it is often difficult to differentiate between bacterial and viral aetiologies in adults
with suspected meningitis. Several studies have demonstrated the potential use of serum procalcitonin
(PCT) in making this differentiation. The aim was to pool these studies into a meta-analysis to determine
the diagnostic accuracy of PCT.
Methods: Major electronic databases were searched for articles studying the use of serum PCT in the
differentiation of bacterial and viral meningitis in adult patients. No date or language restrictions were
applied. Data analysis was performed using Meta-DiSc 1.4 and MIX 2.0.
Results: Nine studies (n = 725 patients) were included in the meta-analysis. Serum PCT was found to be a
highly accurate test for diagnosing meningitis. The pooled sensitivity, specificity, positive likelihood
ratio, negative likelihood ratio, and diagnostic odds ratio (DOR) for PCT were 0.90 (95% confidence
interval (CI) 0.84–0.94), 0.98 (95% CI 0.97–0.99), 27.3 (95% CI 8.2–91.1), 0.13 (95% CI 0.07–0.26), and
287.0 (95% CI 58.5–1409.0), respectively. PCT was found to be far superior to C-reactive protein, which
had a pooled DOR of only 22.1 (95% CI 12.7–38.3).
Conclusions: Serum PCT is a highly accurate diagnostic test that can be used by physicians for rapid
differentiation between bacterial and viral causes of meningitis in adults.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Bacterial meningitis (BM) is a significant cause of morbidity and
mortality worldwide, with 1.2 million cases per year, resulting in
135 000 deaths.1 Due to the high mortality rate and potential
neurological sequelae in survivors, there is an urgent need for rapid
diagnosis with near 100% sensitivity.2 Cerebrospinal fluid (CSF)
analysis is the current gold standard for the diagnosis of BM, along
with biomarkers such as C-reactive protein (CRP) and white blood
cell count (WBC). However, none of these tests achieve 100%
sensitivity and confer a high enough specificity to distinguish
between bacterial and viral meningitis (VM).2
CRP has traditionally been used as the biomarker for
inflammation. However, CRP may show a delayed increase during
the course of bacterial infection, resulting in false-negative tests in
the early stages of the disease.3–6 CRP can also be elevated in viral
infections, limiting its ability to discriminate between bacterial* Corresponding author. Tel.: +48 795 677 090.
E-mail address: bmhenry55@gmail.com (B.M. Henry).
http://dx.doi.org/10.1016/j.ijid.2015.07.011
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).and viral aetiologies of meningitis.7 Procalcitonin (PCT) is now
considered to be the best candidate to replace CRP due to its high
diagnostic accuracy in various infectious pathologies, including
sepsis, acute infectious endocarditis, and pancreatitis.8 Fibronec-
tin, interleukin 6 (IL-6), and tumour necrosis factor alpha (TNF-a)
have also been proposed as potential biomarkers, but have not thus
far been accepted widely for clinical use.9
Normal PCT levels in healthy individuals are <0.1 ng/ml, and
levels increase dramatically in response to bacterial infection.10 It
has been hypothesized that this increase is due to the over-
expression of the CALC-1 gene and increased release of PCT from
various tissues in response to bacterial endotoxins and inflamma-
tory cytokines such as TNF-a, IL-6, and IL-1b.8,11,12 Unlike CRP, PCT
has not been reported to be elevated in viral infections, thus
conferring it the important ability to distinguish easily between
bacterial and viral aetiologies.13
PCT also demonstrates utility in the early diagnosis of
meningitis by rising after 4 h, peaking at 6 h, and remaining
elevated over 24 h.14,15 This is in contrast to CRP, which rises over
6–12 h and peaks at 24–48 h.16,17 This delay in diagnosis,
combined with the traditional 72-h wait for the results of Gramciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Flow chart of study identification, evaluation, and inclusion in the meta-
analysis.
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therapy.18,19 This can lead to potential adverse effects, increased
health care costs, and an increased risk of nosocomial infection.20–22
Several studies have attempted to study the diagnostic accuracy
of PCT in differentiating between BM and VM in adult patients.23–31
The reported results of these studies are varied and a consensus has
yet to be reached on the diagnostic value of PCT in meningitis.
The aim of this study was to pool and analyze the results of all
the reported studies to determine the true diagnostic accuracy of
PCT in adult patients with suspected meningitis.
2. Methods
2.1. Search strategy
In accordance with the PRISMA guidelines, a systematic
literature search of the major electronic databases including
PubMed, Scopus, EMBASE, Science Direct, Web of Science, and the
Cochrane Library was performed to identify studies eligible for the
meta-analysis. The search was specifically tailored to each of the
electronic databases. Search terms included procalcitonin, PCT, S-
PCT, ProCT, meningitis, and meningism. No date or language
restrictions were set. Case reports, letters to the editor, and
conference posters and abstracts were searched, but not included
in the meta-analysis.
2.2. Selection of studies
Studies were eligible for inclusion in the meta-analysis if they
(1) investigated the diagnostic accuracy of PCT in adult patients
with suspected meningitis to distinguish between bacterial and
viral aetiologies, (2) measured serum PCT on admission, and (3)
reported data necessary to construct 2  2 tables (true-positives,
false-positives, false-negatives, true-negatives). Studies were
excluded if they (1) reported incomplete data or did not provide
data necessary to construct 2  2 tables, (2) did not compare BM vs.
VM, (3) had a poor methodological quality as determined using the
Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2)
tool, (4) studied exclusively paediatric populations, or (5) only
measured the levels of PCT in CSF. Three authors (J.V., B.M.H., and
P.K.R.) independently assessed each full-text article for inclusion in
the analysis. Disagreements were resolved by a consensus among
the authors. When necessary, articles were translated from their
original text into English for further review by medical profes-
sionals who are native English speakers and fluent in the language
of the original text.
2.3. Data extraction
Two authors (J.V. and J.R.) independently extracted data from
the selected studies. Extracted data included sample size, mean
age, PCT and CRP cut-offs, sensitivity, specificity, testing method,
time of measurement, serum levels of PCT and CRP, and definitions
of BM. Two by two tables were then constructed to calculate values
of true-positives, false-positives, false-negatives, and true-nega-
tives, to be pooled into the meta-analysis. In the case of studies that
reported multiple cut-offs with sensitivities and specificities, the
cut-off with the highest Youden’s J statistic was used in the meta-
analysis.32 In the case of any discrepancies in the data, the authors
were contacted by e-mail for clarification.
2.4. Quality assessment
Methodological quality was assessed with the QUADAS-2
tool.33 This tool assesses risk of bias and applicability through a
series of signalling questions related to methodological quality ofthe study. Risk of bias is assessed in four domains – patient
selection, index test, reference standard, and flow and timing.
Applicability is assessed by the first three of the aforementioned
domains. Each domain was ranked as high risk, unclear risk, or low
risk individually by two authors (J.V. and J.R.).
2.5. Statistical analysis
The statistical analysis was performed using Meta-DiSc 1.4 and
MIX 2.0 by one of the authors (B.M.H.). Using a random-effects
model, the pooled sensitivities, specificities, positive likelihood
ratios (LR+), negative likelihood ratios (LR), and diagnostic odds
ratios (DOR) were calculated. Summary receiver operating
characteristic (SROC) curves were generated and the area under
the curve (AUC) and Q* index (the point on the SROC curve where
sensitivity and specificity are equal) were then calculated
appropriately. Heterogeneity was assessed using the Higgins I2
test, with values of 25%, 50%, and 75% indicating low, moderate,
and high degrees of heterogeneity, respectively. The threshold
effect was measured using Spearman’s correlation coefficient.34 In
order to further explore heterogeneity, meta-regression was
performed using a single covariate with logDOR as the dependent
variable. To assess publication bias, an asymmetrical funnel plot
was constructed. Due to the current lack of accurate and reliable
tests for publication bias in diagnostic studies, no other assess-
ments were performed.35
3. Results
3.1. Study identification
An overview of the study identification process is given in
Figure 1. Through database searching, 2379 articles were initially
Table 1
Characteristics of studies included in the meta-analysis
Study Population Design Mean
age,
years
Cases (n) Biomarkers
tested
Cut-off
(PCT, ng/ml;
CRP, mg/dl)
Sensitivity (%) Specificity
(%)
TP
(n)
FP
(n)
FN
(n)
TN
(n)
PCT assay
BM VM
Abdelkader
201423
Egyptian Prospective 39 16 24 PCT 1.2 68.8 83.3 11 4 5 20 RayBio Human
Procalcitonin ELISA Kit
Jereb 200124 Slovenian Prospective 55 20 25 PCT 0.5 90 100 18 0 2 25 LUMItest (BRAHMS
Diagnostika, Berlin,
Germany)
CRP 5 90 92 18 2 2 23
Knudsen
200725
Danish Prospective 36.1 10 12 PCT 0.25 90 92 9 1 1 11 Kryptor PCT test
(BRAHMS, Saint-Quen,
France)
CRP 4 90 75 9 3 1 9
Makoo 201026 Iranian Retrospective 46.3 19 31 PCT 0.5 100 87.09 19 4 0 27 VIDAS BRAHMS PCT Assay
Mo 201227 Korean Retrospective 54.9 20 43 PCT 1 90 100 18 0 2 43 VIDAS BRAHMS PCT Assay
CRP 6 85 88 17 5 3 38
Morales
Casado 201428
Spanish Prospective 44 38 33 PCT 0.74 94.7 100 36 0 2 33 ELECSYS BRAHMS PCT
CRP 9 67.5 86.3 26 5 12 28
Ray 200729 French Prospective 52 18 133 PCT 2.13 87 100 16 0 2 133 Kryptor PCT test
(BRAHMS, Saint-Quen,
France)
CRP 2.2 78 74 14 35 4 98
Schwarz 200030 German Prospective 52 16 14 PCT 0.5 69 100 11 0 5 14 LUMItest (BRAHMS
Diagnostika, Berlin,
Germany)
CRP 0.8 94 57 15 6 1 8
Viallon 201131 French Prospective 55 35 218 PCT 0.28 97 100 34 0 1 218 Kryptor PCT test
(BRAHMS, Saint-Quen,
France)
CRP 3.7 86 84 30 35 5 183
BM, bacterial meningitis; VM, viral meningitis; PCT, procalcitonin; CRP, C-reactive protein; TP, true positive; FP, false positive; FN, false negative; TN, true negative.
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were assessed by full text for eligibility in the meta-analysis. Of the
full text articles, nine were deemed eligible for the meta-analysis
and 36 were excluded from the meta-analysis. Two studies by
Viallon et al.36,37 containing overlap of patient data reported in a
later publication31 were excluded. One study looking at the
diagnostic accuracy of PCT in post-neurosurgical meningitis was
also excluded.38
3.2. Study characteristics and quality assessment
The characteristics of the studies included are summarized in
Table 1. A total of nine studies (n = 725 patients) – two
retrospective26,27 and seven prospective23–25,28–31 – were included
in the meta-analysis. Of the studies included, seven were in
English, one in Spanish, and one in Korean. The papers were also
from a wide geographical spectrum, including Egypt, Slovenia,
Denmark, Iran, Korea, Spain, France, and Germany. Only studies on
adult patients were included. The mean age in the studies ranged
from 39 to 55 years.
All studies measured serum PCT levels upon admission in
patients with suspected meningitis to distinguish between a
bacterial or viral aetiology. The cut-off for PCT varied amongst the
studies and ranged between 0.25 ng/ml to 2.13 ng/ml. PCT assay
methods also varied between studies and included the LUMItest
(BRAHMS Diagnostika, Berlin, Germany),24,30 Kryptor test
(BRAHMS, Saint Quen, France),25,29,31 VIDAS BRAHMS PCT as-
say,26,27 RayBio Human Procalcitonin ELISA Kit,23 and ELECSYS
BRAHMS PCT test.28
The reported sensitivities for diagnosing BM in the studies that
measured PCT ranged from 68.8% to 100% and specificities ranged
from 83.3% to 100%. Seven of the nine studies also measured CRP as
a biomarker, with cut-off values ranging from 0.8 mg/dl to 9 mg/dl.
The reported sensitivities of CRP ranged from 67.5% to 90% and
specificities ranged from 57% to 92%.
Overall, the methodological quality among the studies
included was good, and the risk of bias was low. The study
quality assessment using the QUADAS-2 tool is summarized in
Figure 2.Figure 2. Summary of the QUADAS-2 assessment of the studies included.3.3. Diagnostic accuracy indices
The results indicate that serum PCT is a highly accurate test for
the detection of BM. The pooled sensitivity for PCT was 0.90 (95% CI
0.84–0.94), while the pooled specificity for PCT was 0.98 (95% CI
0.97–0.99) (Figure 3). The pooled LR+ was 27.3 (95% CI 8.2–91.1)
and the pooled LR was 0.13 (95% CI 0.07–0.26) (Figure 4A, B). PCT
was found to be a very powerful diagnostic test, with a pooled DOR
equal to 287.0 (95% CI 58.5–1409.0) (Figure 4C). A SROC curve was
also constructed for PCT and the AUC was 0.97 (standard error
(SE) = 0.03) and the Q* index was 0.91 (SE = 0.04) (Figure 4D).
Seven of the nine studies included also assessed the diagnostic
accuracy of CRP in order to compare it with the accuracy of PCT
(n = 635 patients).24,25,27–31 The pooled analysis showed that PCT is
the more accurate and effective diagnostic test. The pooled
sensitivity and specificity for CRP were 0.82 (95% CI 0.75–0.88)
and 0.81 (95% CI 0.77–0.84), respectively (Figure 5). The difference
in specificities indicates that PCT is far stronger at ruling in the
diagnosis of BM as compared to CRP. The AUC for CRP was 0.89
(SE = 0.02) and the Q* index was 0.83 (SE = 0.02). The pooled LR+ of
CRP (4.2, 95% CI 2.8–6.0) was lower than that of PCT, but the pooled
LR of CRP (0.23, 95% CI 0.15–0.35) was similar to that of PCT.
However, the DOR indicates the superiority of PCT, with the DOR of
CRP equal to only 22.1 (95% CI 12.7–38.3).
3.4. Threshold effect and heterogeneity
Significant heterogeneity was detected for the pooled DOR of
serum PCT (I2 = 66.2%). However, heterogeneity was also calculat-
ed for the pooled DOR of CRP and was found to be substantially
lower than the heterogeneity associated with pooled PCT
(I2 = 3.6%). To explore the source of heterogeneity, the threshold
effect was assessed. The calculated Spearmen correlation coeffi-
cient for PCT was r = 0.151 (p = 0.699), indicating that the
threshold effect was not the source of heterogeneity in the PCT
analysis.
It was suspected that the cause of heterogeneity may have
been variation in the type of serum PCT assay used in the
studies. To further explore this hypothesis, a meta-regression
was done to determine if the type of PCT testing assay was
responsible for the heterogeneity. The calculated relative DOR
(RDOR) was 3.42 (95% CI 1.49–7.81, p = 0.01), indicating that the
PCT testing assay was a significant source of heterogeneity
between studies. As such, a subgroup analysis was performed
for each testing method used by at least two different studies in
the analysis. Three studies (n = 426 patients)25,29,31 used the
Kryptor test (BRAHMS Diagnostika), which had the highest
pooled DOR of all PCT assays (DOR 1125.2, 95% CI 77.4–
16362.0), but also the most significant heterogeneity of the
testing assays (I2 = 77.1%). Two studies (n = 75 patients)24,30
used the LUMItest (BRAHMS Diagnostika) (DOR 146.9, 95% CI
17.1–1264.6, I2 = 0.0%) and two studies (n = 113 patients)26,27
used the VIDAS BRAHMS PCT Assay (DOR 385.0, 95% CI 45.2–
3281.2, I2 = 0.0%).
A subgroup analysis was also performed on three studies that
reported a common serum PCT cut-off of 0.5 ng/ml
(n = 125 patients).24,26,30 The pooled sensitivity (0.87, 95% CI
0.76–0.94), specificity (0.94, 95% CI 0.86–0.984), and DOR
(173.4, 95% CI 30.3–992.9) were all lower than in the general
analysis. A second subgroup analysis was performed on two
studies that had a lower PCT cut-off value ranging from
0.25 ng/ml to 0.28 ng/ml (n = 275 patients).25,31 The pooled
sensitivity (0.96, 95% CI 0.85–0.99) and specificity (0.99, 95% CI
0.98–1.0), as well as the DOR (945.3, 95% CI 10.2–87874.0), were
higher than in the three studies with the higher common cut-off
of 0.5 ng/ml.
Figure 3. Pooled sensitivity (A) and specificity (B) for serum procalcitonin for the diagnosis of bacterial meningitis in adults.
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Assessment for potential publication bias was performed using
a funnel plot, which revealed asymmetry among the studies
included (Figure 6).
4. Discussion
Procalcitonin is a 116-amino acid protein, initially discovered as
the precursor molecule of the thyroid hormone calcitonin.39 In
recent years, however, it has become increasingly appreciated as a
reliable marker of bacterial infection due to extensive non-
thyroidal production in response to proinflammatory mediators
such as TNF-a and IL-6.11 Through a proposed cytokine-induced
ubiquitous extrathyroidal upregulation of CALC-1 gene expression,
bacterial infections induce a pervasive PCT release from hepato-
cytes, adipocytes, and various other parenchymal cells.11 Because
of the cytokine-induced recruitment of PCT-producing cells, it has
been suggested that its serum levels may reflect disease severity.40
Due to the serious, time-sensitive nature and high mortality of
BM, diagnostic tests with a high sensitivity and fast turnaround
time are needed. This analysis demonstrates that serum PCT is ahighly accurate diagnostic test for distinguishing between
bacterial and viral aetiologies in patients with suspected meningi-
tis. PCT was found to be a more specific than sensitive marker of
BM. The pooled PCT specificity was 0.98 and LR+ was 27.3,
indicating that PCT is a strong marker for ruling in BM in adult
patients. This is compared to CRP, which had a specificity of
0.81 and LR+ of only 4.2. The likelihood ratio is a diagnostic test
calculated from the sensitivity and specificity, and is an indicator of
the value of performing a diagnostic test. It expresses the degree to
which a diagnostic procedure modifies the probability of a disease.
The range of LR is from 0 to infinity, therefore any values above or
below 1, increase or decrease the likelihood of a disease,
respectively.41
Pooled sensitivities between PCT and CRP were more similar,
however the pooled sensitivity of PCT was still greater than that of
CRP (0.90 vs. 0.82), albeit not significantly. AUC, an overall
assessment of the quality of a diagnostic test, was 0.97 for PCT, as
compared to 0.89 for CRP.
The true power of serum PCT is reflected in the DOR, which is a
single indicator of the accuracy of a diagnostic test, combining data
on both specificity and sensitivity.42 It ranges in value from 0 to
infinity, with higher values reflecting better test performance.42
Figure 4. Pooled positive likelihood ratio (LR+) (A), negative likelihood ratio (LR) (B), diagnostic odds ratio (DOR) (C), and summary receiver operating characteristic (SROC)
(D) for serum procalcitonin for the diagnosis of bacterial meningitis in adults.
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22.1. The strong DOR for serum PCT reflects its clinical utility in
patients with suspected meningitis.
In suspected meningitis, the combined clinical history, physical
examination findings, basic laboratory tests (such as WBC count),
and lumbar puncture results of a patient form the gold standard for
diagnosis. However, clinical symptoms and physical signs are often
not present, and lack the ability to differentiate the aetiology of
meningitis. Nakao et al. reported the sensitivities of fever,
headache, vomiting, and rash for predicting pleocytosis in the
CSF to be only 0.20, 0.91, 0.04, and 0.02, respectively.43
Furthermore, the traditionally used meningeal signs, i.e., Kernig’s
sign, Brudzinski’s sign, and nuchal rigidity, have a low diagnostic
value.44 Brouwer et al.45 reported a pooled sensitivity of Kernig’s
sign in adults to be merely 0.11, while the reported pooled
sensitivities of Brudzinski’s sign and nuchal rigidity were 0.09 and
0.31, respectively. Due to the low sensitivities of physical signs, it is
important to evaluate the entire clinical picture when formulating
a differential diagnosis and determining further appropriate
diagnostic tests.45
In order to confirm a clinical suspicion of meningitis and
determine its aetiology, CSF analysis is considered the gold
standard. However, it was found that the pooled serum PCT
diagnostic accuracy indices in the present study were superior to
those reported for CSF markers by Jereb et al.24. Their reported
serum PCT sensitivity of 0.9 was found to be superior to all
measured CSF parameters, including CSF leukocyte count (0.35),
CSF polymorphonuclear leukocytes (0.45), CSF:blood glucose ratio
(0.85), and CSF protein concentration (0.70). Their reported
specificity of serum PCT of 1.0 was, however, comparable to theother CSF markers, which ranged from 0.96 to 1.0. This demon-
strates that serum PCT allows for more accurate ruling out of BM as
compared to traditional CSF markers.
As such, we recommend the use of a serum PCT assay to
supplement the traditional gold standard combination of clinical
history, physical examination, basic laboratory tests, and CSF
analysis, in order to increase the overall diagnostic accuracy in
differentiating the aetiology of suspected meningitis. Furthermore,
owing to its high sensitivity and specificity, PCT may be helpful in
situations where the conventional tests are unable to reach a
conclusive diagnosis, such as in cases with non-conclusive CSF
findings.
The level of PCT in the CSF has also been studied as a potential
diagnostic biomarker of BM, albeit to a lesser degree than serum
PCT. Three studies have assessed the diagnostic accuracy of PCT in
CSF using the same cut-off value of 0.5 ng/ml.24,26,40 The reported
sensitivities ranged from 0.55 to 1.0, and the reported specificities
in the studies ranged from 0.93 to 1.0. The mechanism by which
the PCT concentration rises in the CSF during BM has been
debated.24,46 However, Konstantinidis et al.40 showed that
increased CSF PCT levels correlate with increased disease severity,
duration, and mortality. Further studies are needed to confirm the
efficacy of CSF PCT as a diagnostic marker of BM and its potential
role as a prognostic marker of mortality.
In order to be widely implemented in the clinical setting, the
economic implications of serum PCT and CRP testing must be
considered. CRP is tested using a wide variety of inexpensive assays
costing between USD $1 and $10.47 However, according to a study
by Nabulsi et al., routine CRP testing inflated hospital bills by USD
$26 715.9, while failing to impact the decision-making process in a
Figure 5. Pooled sensitivity (A) and specificity (B) for C-reactive protein for the diagnosis of bacterial meningitis in adults.
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around 50 min, which can delay the initiation of immediate
interventions.49 On the other hand, PCT assays cost, on average,
around USD $10 to 40,47 and have significantly shorter turnaround
times of around 20 min for the newer PCT testing assays such as
Kryptor (BRAHMS Diagnostika).50 This can be advantageous for the
implementation of appropriate treatment, as well as for avoidingFigure 6. Funnel plot presenting study heterogeneity and potential for publication
bias.unnecessary empirical antibiotic therapy. For example, according
to a review by Agarwal and Schwartz,51 patients being treated for
sepsis in the intensive care unit under PCT-guided interventions
experienced a 28% to 31% reduction in the duration of antibiotic
therapy.
Due to the superior accuracy and power of PCT as compared to
that of CRP, its clinical implementation can be a cost-effective tool
in differentiating between BM and VM. The use of PCT to
supplement the traditional gold standard would allow for the
accurate and rapid differentiation of the aetiology of meningitis,
early in the course of the disease, which could potentially limit the
need for costly interventions such as blood cultures and empiric
antibiotic therapy. The rapid confirmation of a viral aetiology
would also reduce the costs of unnecessary hospitalization and the
treatment of resulting potential nosocomial infections.
Furthermore, serum PCT levels, unlike those of CRP, have not
been shown to be affected by non-steroidal anti-inflammatory
drugs, steroids, or inflammatory comorbidities such as inflamma-
tory bowel disease, systemic lupus erythematosus, or gout.52–55
Additionally, PCT may potentially be useful in discriminating
between bacterial and non-infectious aetiologies of meningitis.
Neuro-Behçet’s disease can mimic BM, presenting with acute
meningeal symptoms and showing polymorphonucleic pleocyto-
sis in the CSF.56 In a case series of seven patients presenting with
neuro-Behçet’s disease by Suzuki et al.,56 the authors found that all
seven patients had elevated CRP levels, but none had an elevated
J. Vikse et al. / International Journal of Infectious Diseases 38 (2015) 68–76 75PCT level. These show yet additional benefits of using serum PCT as
a biomarker, over CRP, in potential bacterial infections.
A few limitations on the clinical use of PCT should also be
mentioned. The use of PCT to differentiate between BM and other
causes of febrile encephalopathy due a bacterial aetiology, such as
a brain abscess, is most likely limited, as PCT is often elevated in the
case of most bacterial infections.8 Furthermore, as PCT is also
elevated in patients with bacterial pneumonia,57 sepsis,58,59 and
other bacterial infections, the diagnostic use of PCT in patients
presenting with acute meningitis in the presence of other bacterial
infections is also potentially limited when compared to CSF
analysis. Thus, physicians should take into account the entire
clinical picture when formulating their diagnosis.
Additionally, PCT levels would be expected to decrease in
patients receiving antibiotics prior to testing, thus giving
misleading results.60,61 Hu et al.62 found that PCT levels decreased
significantly 3 days after the initiation of antibiotic treatment in
children with BM. Furthermore, the authors investigated how
serum PCT levels correlated to disease severity.62 They found
patients with higher serum PCT levels had more severe clinical
symptoms and increased mortality.62 Additionally, in patients who
did not experience clinical improvement after the initiation of
antibiotic therapy, PCT levels did not decrease as significantly as
compared to those who experienced clinical improvement.62
Further studies should examine the use of PCT to assess prognosis,
mortality, and the efficacy of antibiotic therapy in patients with
BM, as well as how antibiotic therapy affects the use of PCT as a
diagnostic marker.
This meta-analysis was limited by the number of studies
available, the potential for publication bias, and the moderate
heterogeneity between the studies included. In this analysis, the
funnel plot did reveal asymmetry, however it is suspected that this
was due to the limited number of studies included in the meta-
analysis. Traditional publication bias assessments, such as Begg’s
test and Egger’s test, are designed to assess bias in interventional
studies, not diagnostic studies, and as such have low power and can
give seriously misleading results.35 This is due to the lack of proper
determinants for measuring publication bias in diagnostic
studies.35 As such, the potential for publication bias in the studies
included cannot be ruled out.
Heterogeneity in the present analysis appears to be due
primarily to the type of PCT assay used in the study. The newest
of the testing methods used in the studies, the Kryptor test
(BRAHMS Diagnostika), had the highest pooled DOR of all the
testing assays used in the analysis, but also had a moderate level of
heterogeneity between the studies using this assay. However, with
a rapid turnaround time of only 20 min and the high DOR, it
represents an excellent assay that can be used clinically to assess
PCT levels.50 Despite the limitations of the meta-analysis, serum
PCT is an excellent tool that can be used to enable quick and
accurate differentiation between BM and VM in adults, and
supplement the clinical history, physical examination, basic
laboratory tests, and CSF analysis for a more accurate diagnosis.
Serum PCT cut-off values in the meta-analysis ranged from
0.25 ng/ml to 2.13 ng/ml. Interestingly, in subgroup analyses, a
reduction in cut-off value from 0.5 ng/ml to a cut-off range of
0.25 ng/ml to 0.28 ng/ml, demonstrated an increase in sensitivity,
specificity, and DOR from 0.87, 0.94, and 173.4 to 0.96, 0.99, and
945.3, respectively. It is suspected that this is due to the use of
the Kryptor test (BRAHMS Diagnostika) PCT assay by both of the
studies with the lower cut-off values, while no studies in the
0.5 ng/ml cut-off subgroup used this PCT assay. The increase in
both sensitivity and specificity at this lower cut-off range as
compared to the general analysis, increases the clinical utility of
this test by increasing the ruling-out power of the PCT assay
needed to accurately exclude BM. As such, the use of a low PCTcut-off of around 0.25 ng/ml with the Kryptor test (BRAHMS
Diagnostika) PCT assay is recommended, which gives both the high
sensitivity and high specificity needed clinically to accurately
diagnose the cause of meningitis. However, further studies are
required to determine the optimal cut-off values for the other PCT
testing assays. Additionally, future studies should assess the
diagnostic role of PCT specifically in suspected cases of meningitis
with non-conclusive CSF findings, in cases of non-infectious
meningitis, and in cases of meningitis caused by opportunistic
pathogens such as Mycobacterium tuberculosis.
5. Conclusions
Serum PCT is a powerful diagnostic test for the assessment of
suspected meningitis, allowing rapid differentiation between
bacterial and viral aetiologies, and earlier initiation of appropriate
and necessary therapies. The evidence suggests that while serum
PCT offers a similar specificity to the traditionally used CSF markers
of meningitis, it confers a higher sensitivity. Thus PCT, when used
as a supplement to clinical signs and CSF analysis, allows for a more
accurate overall diagnosis in patients with suspected meningitis.
Lastly, this analysis indicates that PCT is a far superior diagnostic
biomarker than the traditionally used marker of inflammation,
CRP. The use of PCT serum assays in adult patients with suspected
meningitis is therefore recommended.
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